Removes stroke-causing blood clots from brain arteries using catheters that suck the clot out.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
Removes stroke-causing blood clots from brain arteries using catheters that suck the clot out.
Penumbra makes catheters that remove stroke-causing clots from cerebral arteries by threading a wide, flexible tube through the brain's tortuous blood vessels and applying continuous suction — a technique that requires the catheter tip to be engineered specifically for each vessel anatomy rather than built as one universal design. Because each distinct tip geometry counts as a new device under FDA rules, every new configuration needs its own 510(k) clearance taking 90 to 180 days, so clinical demand for anatomy-specific catheters consistently runs ahead of what Penumbra can actually ship. Hospitals that adopt the system integrate Penumbra's suction pump hardware directly into their imaging suites, and the interventional neuroradiologists who use it develop catheter-handling skills — controlling suction force through a large-bore shaft in a narrow, curved vessel — that are physically different from the grab-and-pull technique used with competing stent-retriever devices, meaning both the equipment and the physician workforce would have to be retrained simultaneously before a stroke center could switch platforms. The whole business depends on aspiration-first remaining the clinically accepted standard of care: if randomized trial evidence were to show that combining aspiration with a stent retriever produces better outcomes than aspiration alone, the engineering that distinguishes Penumbra from its competitors would be reclassified as an incomplete approach, and the training and hardware entrenchment that currently makes switching impractical would dissolve with it.
How does this company make money?
Penumbra earns revenue each time a hospital purchases a single-use aspiration catheter, which is consumed in every procedure and must be replaced. It also sells reusable aspiration pump systems to hospitals. The bulk of revenue comes from comprehensive stroke centers that run multiple thrombectomy procedures every day, making those high-volume centers the most important customers.
What makes this company hard to replace?
Interventional neuroradiologists must complete specific training on aspiration technique and large-bore catheter handling that is physically different from the skills used with stent-retriever systems — that training is not transferable. Hospital catheterization labs also integrate Penumbra's aspiration pump hardware directly into their imaging systems, and switching to a different thrombectomy platform would require a full requalification of that equipment. Both of those barriers must be overcome at the same time for a switch to happen.
What limits this company?
Every time Penumbra engineers a catheter tip suited to a new vessel location, that tip must go through a separate FDA 510(k) review that takes 90 to 180 days. The tip design process itself cannot be automated — it requires repeated physical testing against models of real brain anatomy. These two steps happen one after the other, which means hospital demand for anatomy-specific catheters consistently outpaces how fast Penumbra can get new versions approved and shipped.
What does this company depend on?
Penumbra cannot operate without FDA 510(k) clearance for each catheter configuration, biocompatible polymer tubing that meets USP Class VI standards, specialized aspiration pump components, interventional neuroradiology training programs at hospitals, and stroke centers that maintain 24/7 catheterization lab availability.
Who depends on this company?
Comprehensive stroke centers depend on Penumbra's devices to perform mechanical thrombectomy. If those devices were unavailable, those hospitals would have to fall back on tissue plasminogen activator drugs, which are less effective at clearing large vessel blockages. Interventional neuroradiologists would lose their primary tool for treating large vessel occlusions, and stroke patients would face lower survival rates and worse recovery outcomes.
How does this company scale?
Standardized catheter shaft components and aspiration pump systems can be manufactured in higher volumes using normal medical device production methods, so that part of the business scales reasonably well. What does not scale is catheter tip design: optimizing a tip for a specific vessel anatomy requires iterative physical testing against neuroanatomical models and cannot be automated. As Penumbra adds more product configurations, that engineering process becomes a compounding bottleneck.
What external forces can significantly affect this company?
Medicare reimbursement rates for CPT code 61645, the billing code for mechanical thrombectomy, directly influence how often hospitals perform the procedure and how much they are willing to spend on devices. If those rates fall, procedure volumes and purchasing budgets follow. On the other side, aging populations in developed countries are increasing the number of strokes each year, pushing demand growth faster than Penumbra can expand manufacturing capacity.
Where is this company structurally vulnerable?
If prospective randomized clinical trial evidence were to show that combining aspiration with a stent-retriever produces better patient outcomes than aspiration alone, hospital stroke programs would face a clinical obligation to adopt that hybrid approach. That finding would recast Penumbra's large-bore aspiration-only engineering from a clinical advantage into an incomplete method, and the physician training and pump integration that currently make switching costly would no longer be enough reason to stay.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph